Tyrosine kinases play a pivotal role in oncogenesis. Although tyrosine kinase inhibitors as
sunitinib malate are used in cancer therapy, emerging studies report compromised
cytotoxicity when used as monotherapy and thus combinations with other anti-cancer agents
is recommended. Chloroquine is a clinically available anti-malarial agent which has been
shown to exhibit anti-cancer activity. In the current study, we questioned whether
chloroquine can modulate sunitinib cytotoxicity. We found that chloroquine synergistically …